Significant Progress for Pluristem: PLX Cells Were Selected for European Medicines Agency's Adaptive Pathways Pilot Project

Pluristem is Targeting Critical Limb Ischemia as the First Indication for Initial Marketing Authorization, Potentially Substantially Shortening the Time to Market of PLX Cells Via the Adaptive Pathways